ReviewCurrent allergy and asthma reports2026
MicroRNAs as current diagnostic biomarkers and potential therapeutic targets in allergic and non-allergic rhinitis - A functional characterization.
Review in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAllergic rhinitis affects up to one-quarter of the population in industrialized countries. This chronic inflammatory disease of the nasal mucosa is triggered by allergen exposure and mediated by immunoglobulin E, leading to immune dysregulation. Diagnosis typically relies upon skin prick tests, serum-specific immunoglobulin E levels and nasal allergen provocations. Differentiation from non-allergic rhinitis remains a diagnostic challenge. Recent research has identified novel microRNAs, small non-coding RNA regulating post-transcriptional gene expression, as key regulators of immunological pathways with great potential as disease-specific targets in diagnostics and therapy. The purpose of this review is to explore novel therapeutic and diagnostic possibilities regarding novel miRNAs. RECENT
findingsThis functional review evaluated current evidence specific to miRNA expression in allergic and non-allergic rhinitis. Seven microRNAs (miR-29a, miR-135a, miR-143, miR-146a, miR-150-5p, miR-223, miR-451) are discussed as potential diagnostic markers and therapeutic agents in the future. Interventional studies, including human and animal studies, are reviewed. The available evidence suggested that selected microRNAs may show specificity and sensitivity as biomarkers for allergic and non-allergic rhinitis in future human trials. Therapeutic options involving miRNAs have shown great promise but still lack validation in clinical studies. In this review, we have identified several challenges in microRNA-based diagnostic approaches and suggested strategies to facilitate future development. MiRNA research in AR has revealed their role as both diagnostic biomarkers and therapeutic agents in several different mechanisms that are currently under investigation. Dysregulation of miRNA expression has been documented in asthma and allergic rhinitis, but data regarding non-allergic rhinitis remain limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.